Oncobit, the medtech firm based in Schlieren in the canton of Zurich, has concluded a service agreement with the British biotechnology company Immunocore. The partnership between the two companies will seek to improve the use and understanding of circulating tumor DNA (ctDNA) analysis as a reliable, real-time therapy response marker in clinical trials, further details of which can be found in a press release.
To this end, the British company, which focuses on the development and provision of innovative immunomodulating medicines and has operated a branch office in Risch-Rotkreuz in the canton of Zug since 2022, will in future rely on the digital platform developed by the spin-off from the University of Zurich. According to information from the company itself, the platform offers a unique combination of proprietary digital PCR (Polymerase Chain Reaction) assays and software.
PCR is a laboratory technique for quickly producing millions or even billions of copies of a specific section of DNA, which can then be examined in more detail. According to the press release, Oncobit’s aim is to optimize therapy management and transform cancer care in a cost and time-efficient manner by quantifying specific cancer markers in liquid biopsies.
“We are excited to collaborate with Immunocore, a company that shares our vision for innovation in pioneering cancer care”, as Dr. Claudia Scheckel, CEO of Oncobit, explains in the press release. She adds: “By contributing to such studies, we are proud to work towards our goal of improving patient outcomes with high-precision and cutting-edge cancer monitoring solutions.”
